Sun Pharma gets Brazil approval to make, market semaglutide

Regulatory product approvalBusiness Updates View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹1991.40

prior close

₹1993.10

announcement price

After-mkt

timing

Nifty 100market+0.2%+0.4% vs market

Pharmaceuticals peers, median of 162sector-0.8%+1.5% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty 100 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.7

15m

+0.6

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+0.2+0.4-0.8+1.5

Next day

-0.3+0.7-1.0-0.5+0.2

-2.3+2.3-4.6+0.2-2.5

-1.4+1.6-3.0+0.1-1.5

-2.6+1.7-4.3+0.5-3.1

-2.0+1.8-3.8+0.7-2.7

-2.4+1.7-4.0+1.4-3.8

15d

-4.5+0.3-4.8+0.4-4.9

-0.3-0.3-0.0+1.7-2.1

-8.8-6.2-2.6+3.0-11.8

-10.7pendingpending-2.4-8.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma got approval from Brazil's ANVISA to manufacture and market semaglutide injection for type 2 diabetes. Launch planned within days via partnership with Hypera Pharma. Product offered as pre-filled multi-dose pen, once-weekly dosing in two strengths. Brazil's semaglutide market is around USD 413 million (IQVIA). This strengthens Sun's diabetes portfolio in LATAM.

Likely market impact

Positive - opens access to about USD 413M Brazil semaglutide market; strengthens LATAM portfolio and revenue opportunity.